The role of heat shock proteins in predicting the course of the climacteric syndrome
DOI:
https://doi.org/10.15574/HW.2022.161.43Keywords:
perimenopause, climacteric syndrome, menopausal hormone therapy, HSP60, GroElAbstract
The problem of menopause has been relevant for many decades. A pathogenetically justified method of treatment, taking into account the change in the hormonal background of a woman, is hormone replacement therapy. Determination of immune markers of cellular homeostasis is one of the promising directions, therefore, the study of changes in the levels of antibodies to HSP60 can become a reliable marker of both the course and compensation of disorders of the neurovegetative state in perimenopause.
Purpose - to study the role of anti-Müllerian, follicle-stimulating, luteinizing, thyroid-stimulating hormones, antibodies (IgG) to human heat shock protein 60 (HSP60) and its bacterial homologue (GroEl), and obstetric history on the diagnosis and treatment of vasomotor symptoms in perimenopausal women.
Materials and methods. 158 patients with climacteric syndrome in perimenopause were examined in the period October 2019 - March 2022. The Group 1 (main) included 80 patients who agreed to treatment and received it according to the standard scheme: combined treatment in a cyclical regimen - estrogens (17β-estradiol) + progestogens (dydrogesterone); the Group 2 (comparison) included 78 women who refused treatment due to estrogen deficiency.
Results. Revealed a decrease (p<0.01) in the risk of not achieving a high treatment effect with vasomotor symptoms for treated patients, OR=0.04 (95% CI: 0.01-0.18) compared to the group of untreated patients. With the number of deliveries, the risk of not achieving a high treatment effect in women with vasomotor symptoms increases (p=0.01), OR=2.27 (95% CI: 1.2-4.27) for each delivery. A lower (p=0.039) risk of not achieving a high treatment effect was found in women with vasomotor symptoms at a higher GroEl level, ОR=0.994 (95% CI: 0.987-1.000) for each ng. When standardizing by the thyrotropin hormone and the manifestation of vasomotor symptoms before or without treatment, a decrease (p<0.001) in the risk of not achieving a high effect of treatment in women with vasomotor symptoms for treated patients was found, OR=0.04 (95% CI: 0.01-0.20).
Conclusions. This study found that there is no informative indicator for predicting the effectiveness of treatment in women with vasomotor symptoms. It was established that the HSP60 indicator does not affect, and the GroEl indicator affects the effectiveness of the treatment of vasomotor clinical manifestations.
The research was carried out in accordance with the principles of the Declaration of Helsinki. The study protocol was approved by the Local Ethics Committee of the institutions. The informed consent of the women was obtained for conducting the studies.
No conflict of interest was declared by the authors.
References
Bauer M, Heinz A, Whybrow PC. (2002). Thyroid hormones, serotonin, and mood: synergy and significance in the adult brain. Mol Psychiatry. 7 (2): 140-156. https://doi.org/10.1038/sj.mp.4000963; PMid:11840307
Benhalima K, Van Crombrugge P, Moyson C et al. (2018). A modified twostep screening strategy for gestational diabetes mellitus based on the 2013 WHO criteria by combining the glucose challenge test and clinical risk factors. J Clin Med. 7 (10). pii:E351. https://doi.org/10.3390/jcm7100351; PMid:30322138 PMCid:PMC6210855
Berestoviy V, Mahmood A, Venckivska I, Ginzburg V, Sokol I, Berestoviy O, Govsieiev D. (2021). The overview and role of heat shock proteins (HSP) especially HSP 60 and 70 in reproduction and other pathologies (a literature review). Medicni perspektivi. 26 (1): 54-62. https://doi.org/10.26641/2307-0404.2021.1.227733
De Villiers T, Tatarchuk T, Avramenko N, Bulavenko O, Gabal V et al. (2016). National consensus on management of female patients in menopause. Reproductive endocrinology. 27: 8-25. https://doi.org/10.18370/2309-4117.2016.27.8-25
Del Ghianda S, Tonacchera M, Vitti P. (2014). Thyroid gland and menopause. Menopause. 17 (3): 225-234. https://doi.org/10.3109/13697137.2013.838554; PMid:23998691
Dillon KE, Gracia CR. (2013). What is normal ovarian reserve? Seminars in reproductive medicine. 31 (6): 427-436. https://doi.org/10.1055/s-0033-1356478; PMid:24101223
Fait T. (2019). Menopause hormone therapy: latest developments and clinical practice. Drugs in context: 8. https://doi.org/10.7573/dic.212551; PMid:30636965 PMCid:PMC6317580
Ferrell RJ, Simon JA, Pincus SM et al. (2006). The length of perimenopausal menstrual cycles increases later and to a greater degree than previously reported. Fertil Steril. 86: 619-624. https://doi.org/10.1016/j.fertnstert.2006.01.045; PMid:16889776
Hall JE. (2015). Endocrinology of the Menopause. Endocrinol Metab Clin North Am. 44 (3): 485-496. https://doi.org/10.1016/j.ecl.2015.05.010; PMid:26316238 PMCid:PMC6983294
Kase NG. (2009). Impact of hormone therapy for women aged 35-65 years, from contraception to hormone replacement. Gend Med. 6 (1): 37-59. https://doi.org/10.1016/j.genm.2009.02.001; PMid:19318218
Kelsey TW, Wright P, Nelson SM, Anderson RA, Wallace WHB. (2011). A validated model of serum anti-müllerian hormone from conception to menopause. PloS one. 6 (7): e22024. https://doi.org/10.1371/journal.pone.0022024; PMid:21789206 PMCid:PMC3137624
Makarenko M, Govsieiev D, Vorona R, Tsisarenko A, Vasil'tchuk O et al. (2016). Identification and characterization of antibodies against human HSP60 at pregnancy. Health of woman. 8 (114): 75-75. https://doi.org/10.15574/HW.2016.114.75
Oi N, Ohi K. (2013). Comparison of menopausal symptoms and thyroid disease symptoms in Japanese women aged 35-59 years. Climacteric. 16 (5): 555-560. https://doi.org/10.3109/13697137.2012.717995; PMid:23025806
Partyka Ł, Hartwich J, Kieć-Wilk B, Polus A, Wybrańska I, Dembińska-Kieć A. (2001). Is atherosclerosis an autoimmunological process? Przeglad Lekarski. 58 (12): 1067-1070.
Pinkerton J. (2017). The NAMS 2017 Hormone Therapy Position Statement Advisory Panel. The North American Menopause Society, New York. 24 (7): 728-753. https://doi.org/10.1097/GME.0000000000000921; PMid:28650869
Rajtar-Ciosek A, Kacalska-Janssen O, Zmaczyński A, Wyroba J et al. (2015). Reduction in the level of antibodies against heat shock proteins 60 during different hormonal protocols in postmenopausal women. Menopause Review/Przegląd Menopauzalny. 14 (4): 218-222. https://doi.org/10.5114/pm.2015.56402; PMid:26848292 PMCid:PMC4733899
Razvi S, Shakoor A, Vanderpump MPJ et al. (2008). Effect of age on the association between subclinical hypothyroidism and coronary heart disease: a meta-analysis. J Clin Endocrinol Metab. 93: 2998-3007. https://doi.org/10.1210/jc.2008-0167; PMid:18505765
Santoro N. (2017). Using Antimüllerian hormone to predict fertility. Jama. 318 (14): 1333-1334. https://doi.org/10.1001/jama.2017.14954; PMid:29049571
Surks MI, Hollowell JG. (2007). Age distribution of serum thyrotropin and antithyroid antibodies in the US population: implications for the prevalence of subclinical hypothyroidism J Clin Endocrinol Metab. 92: 4575-4582. https://doi.org/10.1210/jc.2007-1499; PMid:17911171
Troìa L, Martone S, Morgante G, Luisi S. (2020). Management of perimenopause disorders: hormonal treatment. Gynecological Endocrinology. 37: 3. https://doi.org/10.1080/09513590.2020.1852544; PMid:33263443
Downloads
Published
Issue
Section
License
Copyright (c) 2022 Ukrainian Journal Health of Woman
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
The policy of the Journal UKRAINIAN JOURNAL «HEALTH OF WOMAN» is compatible with the vast majority of funders' of open access and self-archiving policies. The journal provides immediate open access route being convinced that everyone – not only scientists - can benefit from research results, and publishes articles exclusively under open access distribution, with a Creative Commons Attribution-Noncommercial 4.0 international license (СС BY-NC).
Authors transfer the copyright to the Journal UKRAINIAN JOURNAL «HEALTH OF WOMAN» when the manuscript is accepted for publication. Authors declare that this manuscript has not been published nor is under simultaneous consideration for publication elsewhere. After publication, the articles become freely available on-line to the public.
Readers have the right to use, distribute, and reproduce articles in any medium, provided the articles and the journal are properly cited.
The use of published materials for commercial purposes is strongly prohibited.
